Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Chronic kidney disease (CKD) is the gradual loss of kidney function over a period of several years. Due to kidney failure, the organ’s function is severely impaired, which leads to accumulation of dangerous levels of waste and fluid in the body. Early detection can help prevent the progression of kidney to kidney failure. The treatment for CKD is aimed at stopping or slowing down the progression of the disease. Diuretics, RAS Blockade, β – Blockers, Calcium Channel Blockers etc. are some of the major drug used for the treatment of chronic kidney disease or its underlying cause.

Global Hypertension in CKD Market - Impact of the Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it as a public health emergency. As the COVID-19 cases are surging, the risk for patients acquiring chronic kidney disease is also increasing. For instance, according to a study conducted in May 2020, by the researchers at Mount Sinai Health System, New York City, U.S., occurrence of kidney disease might increase as a post-COVID-19 effect in most of the COVID-19 positive patients. Moreover, according to the National Kidney Foundation, a study found that COVID-19 positive patients hospitalized in the span of March 11 and April 26, 2020, were likely to develop acute kidney injury (AKI) twice non-COVID patients.

COVID-19 pandemic is expected to hamper growth of the global hypertension in CKD market during the forecast period. According to the Indian Journal of Medical Sciences, June 6, 2020, the COVID-19 pandemic has affected the conduction of clinical trials due to unavailability of trial site staff, restrictions for travelling, investigational product availability, and others. These challenges are hindrances for developing new treatment for the patients suffering from hypertension with CKD.

The global hypertension in CKD market is estimated to be valued at US$ 191.8 Mn in 2020 and is expected to exhibit a CAGR of 10.6% over the forecast period (2020-2027).

Figure 1: Global Hypertension in CKD Market Share (%) Analysis, By Product Type, 2020

Hypertension in CKD  | Coherent Market Insights

Market players are engaged in inorganic activities such as collaboration, in order to conduct research and development activities for various types of diseases, by combining their expertise and investment, which is expected to drive the growth of the global hypertension in CKD market

Key players are indulged in collaboration, in order to conduct clinical trials for different diseases. For instance, in 2019, Boehringer Ingelheim collaborated with Eli Lilly and Company, in order to develop and commercialize Jardiance (empagliflozin), for the treatment of type 2 diabetes, heart failure, and chronic kidney disease. Currently, the companies, jointly, are conducting clinical trials to evaluate the safety and efficacy of Jardiance in people suffering from heart failure or chronic kidney disease, including in people with and without type 2 diabetes. 

request-sample

Hypertension in CKD Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 191.8 Mn
Historical Data for: 2017 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 10.6% 2027 Value Projection: US$ 388.3 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Class: Diuretics, RAS Blockade, β - Blockers, Calcium Channel Blockers, Others.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Companies covered:

Sanofi S.A, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, AstraZeneca Plc, Novartis International AG, C.H. Boehringer Sohn AG & Ko. KG, Kissei Pharmaceutical Co., Ltd., Reata Pharmaceuticals, Inc., Ardelyx, and KBP Biosciences Holdings Limited

Growth Drivers:
  • Increasing collaboration for conducting research and development activities
  • Rising number of product launches
  • Increasing prevalence of chronic kidney diseases
Restraints & Challenges:
  • Lack of awareness about chronic kidney disease

Market players are indulged in launching new products for the treatment of Hyperphosphatemia in patients suffering from chronic kidney disease, which is expected to drive the growth of the global hypertension in CKD market over the forecast period

Increasing product launches by key players is expected to drive growth of the market over the forecast period. For instance, in 2018, Kissei Pharmaceutical Co., Ltd. launched P-TOL Granules (Sucroferric oxyhydroxide) 250 mg and 500 mg, in Japan for the treatment of hyperphosphatemia, in patients suffering from chronic kidney disease. According to the National Center for Biotechnology Information: 2018, hyperphosphatemia in dialysis patients is associated with vascular wall stiffness, which leads to hypertension. 

Global Hypertension in CKD Market – Restraints

Lack of awareness about chronic kidney disease is the major factor that is expected to restrain growth of the global hypertension in CKD market over the forecast period. Despite the attempts made by governments in order to increase awareness among the population about chronic kidney disease (CKD) through different ways: such as dissemination of clinical practice guidelines and recommendations for patients with CKD or its risk factors, community awareness on events such as World Kidney Day, and free screening for high-risk individuals such as Kidney Early Evaluation Program (KEEP), it has been found that the awareness of CKD among the population remains unacceptably low.

For instance, in March 2018, according to the study published in the BMC Public Health, for chronic kidney disease evaluation, it was reported that the people in Australia have very poor understanding of chronic kidney disease (CKD) and only half of the participants knew about the availability of medications and also, their role in slowing down the worsening of CKD. 

Global Hypertension in CKD Market – Regional Analysis

On the basis of region, the global hypertension in CKD market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to hold dominant position in the global hypertension in CKD market, owing to the reimbursement policy for chronic kidney diseases in the region. For instance, on September 18, 2020, Centers for Medicare & Medicaid Services (CMS), a federal agency within the United States Department of Health and Human Services, announced the new Medicare model for the end-stage renal disease (ESRD), which is also called as the last stage of the chronic kidney disease. The model is End-Stage Renal Disease (ESRD) Treatment Choices (ETC) Model. The model encourages increased use of home dialysis and kidney transplants to help improve the quality of life of Medicare beneficiaries with ESRD. Moreover, this model will be implemented on January 1, 2021 and it is estimated that due to implementation of the model, US$ 23 million will be saved over a period of five and a half years.

Moreover, according to the National Institute of Diabetes and Digestive and Kidney Diseases: 2020, approximately 108 million people in the U.S. are suffering from high blood pressure or hypertension. According to the same source, the following pie chart depicts the factors responsible for the cause of kidney failure in patients suffering from chronic kidney disease, in the U.S.

Hypertension in CKD  | Coherent Market Insights

Furthermore, Europe is also estimated to witness significant growth in the hypertension in CKD market, owing to increasing prevalence of chronic kidney diseases in the region. For instance, according to the article published in Lancet Journal: 2020, increasing prevalence of CKD was reported, in 2017, in different regions of Europe. The following graph depicts the number of people suffering from CKD in Europe.

Hypertension in CKD  | Coherent Market Insights

Figure 2: Global Hypertension in CKD Market (US$ Mn), by Region, 2020

Hypertension in CKD  | Coherent Market Insights

Global Hypertension in CKD Market – Competitive Landscape

Major players operating in the global hypertension in CKD market include Sanofi S.A, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, AstraZeneca Plc, Novartis International AG, C.H. Boehringer Sohn AG & Ko. KG, Kissei Pharmaceutical Co., Ltd., Reata Pharmaceuticals, Inc., Ardelyx, and KBP Biosciences Holdings Limited.

Persons with CKD have significantly higher rates of morbidity, mortality, hospitalizations, and healthcare utilization. Chronic kidney disease may be caused due to comorbid conditions such as high blood pressure, etc. This can lead to buildup of metabolic wastes in patient’s blood and make them feel sick. Chronic kidney disease complications include high blood pressure, anemia (low blood count), weak bones, poor nutritional health, and nerve damage. Chronic kidney disease also increases the risk of developing heart and blood vessel diseases such as heart attack, stroke, etc. These problems may happen slowly over a long period of time.

Market Dynamics

Key players are involved in announcing their results for the clinical trials conducted for the antihypertensive drugs, in order to find the treatment for hypertension in patients suffering from chronic kidney disease. For instance, in 2018, Novartis International AG announced positive results for Entresto (sacubitril/valsartan). According to the clinical trials conducted by the company, it was found that Entresto (sacubitril/valsartan) helped to preserve kidney function in patients suffering from cardiovascular diseases. Moreover, Entresto (sacubitril/valsartan) belongs to angiotensin receptor blockers (ARBs) drug class.

The increasing number of patients undergoing dialysis treatment is expected to drive growth of the global hypertension in CKD market. For instance, according to the data published in the Indian Journal of Public Health (IJPH), in 2018, around 130,000 patients received dialysis treatment in India and the number increased by around 232 patients per million population in India as compared to 2017.

Key features of the study:

  • This report provides an in-depth analysis of global hypertension in CKD market , provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2020-2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global hypertension in CKD market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
  • Key companies covered as a part of this study include Sanofi S.A, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, AstraZeneca Plc, Novartis International AG, C.H. Boehringer Sohn AG & Ko. KG, Kissei Pharmaceutical Co., Ltd., Reata Pharmaceuticals, Inc., Ardelyx, and KBP Biosciences Holdings Limited
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global hypertension in CKD market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the hypertension in CKD market

Detailed Segmentation:

  • Global Hypertension in CKD Market, By Drug Class:
    • Diuretics
    • RAS Blockade
    • β - Blockers
    • Calcium Channel Blockers
    • Others
  • Global Hypertension in CKD Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Hypertension in CKD Market, By Region:
    • North America
      • By Drug Class:
        • Diuretics
        • RAS Blockade
        • β - Blockers
        • Calcium Channel Blockers
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Drug Class:
        • Diuretics
        • RAS Blockade
        • β - Blockers
        • Calcium Channel Blockers
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Class:
        • Diuretics
        • RAS Blockade
        • β - Blockers
        • Calcium Channel Blockers
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Class:
        • Diuretics
        • RAS Blockade
        • β - Blockers
        • Calcium Channel Blockers
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
    • Middle East
      • By Drug Class:
        • Diuretics
        • RAS Blockade
        • β - Blockers
        • Calcium Channel Blockers
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Class:
        • Diuretics
        • RAS Blockade
        • β - Blockers
        • Calcium Channel Blockers
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Sanofi S.A*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Teva Pharmaceutical Industries Ltd.
    • Eli Lilly and Company
    • AstraZeneca Plc
    • Novartis International AG
    • H. Boehringer Sohn AG & Ko. KG
    • Kissei Pharmaceutical Co., Ltd.
    • Reata Pharmaceuticals, Inc.
    • Ardelyx,
    • KBP Biosciences Holdings Limited

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Class
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Epidemiology
    • Key Developments
    • Pipeline analysis
    • Regulatory Scenario
    • Reimbursement Scenario
    • PEST Analysis
    • Treatment Approaches
    • Mergers and Acquisitions Scenario
  4. Global Hypertension in CKD Market - Impact of Coronavirus (Covid-19) Pandemic
    • During COVID-19 Market Situation
    • Supply Side and Demand Side Analysis
    • Government Initiatives for Management of Hypertension in Chronic Kidney Disease (CKD)
  5. Global Hypertension in CKD Market, By Drug Class, 2016-2027 (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 - 2027
      • Segment Trends
    • Diuretics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • RAS Blockade
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • β - Blockers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Calcium Channel Blockers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  6. Global Hypertension in CKD Market, By Distribution Channel, 2016 - 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 - 2027
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  7. Global Hypertension in CKD Market, By Region, 2016 - 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017 - 2027
      • Regional Trends
    • North America
      • Market Size and Forecast, By Drug Class , 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel , 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Drug Class , 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel , 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Drug Class , 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel , 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
        • Germany
        • K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Class , 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel , 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Drug Class , 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel , 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Drug Class , 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel , 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016 - 2027 (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  8. Competitive Landscape
    • Company Profiles
      • Sanofi S.A
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Teva Pharmaceutical Industries Ltd.,
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Eli Lilly and Company
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • AstraZeneca Plc,
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Novartis International AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • H. Boehringer Sohn AG & Ko. KG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Kissei Pharmaceutical Co., Ltd
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Reata Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Ardelyx
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • KBP Biosciences Holdings Limited
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
    • Analyst Views
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 32 market data tables and 25 figures on "Hypertension in CKD Market” - Global Forecast to 2027”.

Frequently Asked Questions

The global hypertension in CKD market is expected to exhibit a CAGR of 10.6% during the forecast period (2020-2027).
The market is estimated to be valued at US$ 191.8 Mn in 2020.
Sanofi S.A, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, AstraZeneca Plc, Novartis International AG, C.H. Boehringer Sohn AG & Ko. KG, Kissei Pharmaceutical Co., Ltd., Reata Pharmaceuticals, Inc., Ardelyx, and KBP Biosciences Holdings Limited are some of the prominent players operating in the market over the forecast period.
The market is expected to be valued at US$ 388.3 Mn in 2027.
RAS blockade is the first line antihypertensive agents in the market.
North America is the prominent region in the market.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner